What's new? Log in Free sign up

Nuvalent (NUVL)

Company Profile

Company profile

Ticker

NUVL

Exchange

Website

www.nuvalent.com

CEO

Dr. James R. Porter Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

NB Merger Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Nuvalent Securities Corporation ...

NUVL stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$129.50

Low target

$125.00

High target

$134.00

Latest filings (excl ownership)

View all

Restricted Stock Unit Award Agreement

Quarterly report

12 Nov 24

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Submission of Matters to a Vote of Security Holders

Latest ownership filings

View all

James Richard Porter

Alexandra Balcom

Henry E. Pelish

James Richard Porter

Andrew A. F. Hack

Notice of proposed sale of securities

Notice of proposed sale of securities

Alexandra Balcom

Financial summary

Financial statements Chart NUVL financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	369.24 mm	369.24 mm	369.24 mm	369.24 mm		369.24 mm
Cash burn (monthly)	(no burn)	(no burn)	28.10 mm	18.51 mm		7.44 mm
Cash used (since last report)	n/a	n/a	78.41 mm	51.64 mm		20.76 mm
Cash remaining	n/a	n/a	290.84 mm	317.60 mm		348.49 mm
Runway (months of cash)	n/a	n/a	10.3	17.2		46.8

Beta Read what these cash burn values mean

Financial data from Nuvalent earnings reports.

Institutional ownership, Q3 2024

NUVL institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	195	176	+10.8%
Opened positions	48	27	+77.8%
Closed positions	29	32	-9.4%
Increased positions	73	72	+1.4%
Reduced positions	52	55	-5.5%

13F shares	Current	Prev Q	Change
Total value	6.98 tn	4.89 tn	+42.8%
Total shares	97.80 mm	93.57 mm	+4.5%
Total puts	619.30 k	131.30 k	+371.7%
Total calls	449.50 k	527.40 k	-14.8%
Total put/call ratio	1.4	0.2	+453.4%

Largest owners	Shares	Value	Change
Flynn James E	25.58 mm	$1.83 bn	0.0%
Deerfield Management	19.99 mm	$2.05 tn	0.0%
FMR	9.65 mm	$987.64 bn	+8.9%
Paradigm Biocapital Advisors	5.00 mm	$511.50 bn	+9.4%
Vanguard	4.13 mm	$422.87 bn	+9.5%
BLK BlackRock	3.62 mm	$370.84 bn	NEW
Perceptive Advisors	2.98 mm	$304.78 bn	+16.9%
Bain Capital Life Sciences Investors	2.70 mm	$275.93 bn	0.0%
Bain Capital Life Sciences Fund II	2.40 mm	$183.98 mm	0.0%
Fairmount Funds Management	1.69 mm	$172.59 bn	-12.3%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	3.62 mm	+3.62 mm	NEW
BLK BlackRock	0.00	-3.02 mm	EXIT
FMR	9.65 mm	+786.26 k	+8.9%
Commodore Capital	940.00 k	-547.76 k	-36.8%
Perceptive Advisors	2.98 mm	+430.16 k	+16.9%
Paradigm Biocapital Advisors	5.00 mm	+428.32 k	+9.4%
Wellington Management	1.01 mm	+400.40 k	+65.5%
Vanguard	4.13 mm	+357.61 k	+9.5%
Norges Bank	0.00	-332.68 k	EXIT
T. Rowe Price	1.08 mm	+328.14 k	+43.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NUVL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Dec 24	James Richard Porter	Class A Common Stock	Option exercise	Acquire M	No	No	0.65	22,000	14.30 k	210,113
19 Dec 24	James Richard Porter	Stock Option Class A Common Stock	Option exercise	Dispose M	No	No	0.65	22,000	14.30 k	565,942
17 Dec 24	Alexandra Balcom	Class A Common Stock	Option exercise	Acquire M	No	No	6.89	8,972	61.82 k	47,000
17 Dec 24	Alexandra Balcom	Class A Common Stock	Option exercise	Acquire M	No	No	1.08	4,728	5.11 k	38,028
17 Dec 24	Alexandra Balcom	Stock Option Class A Common Stock	Option exercise	Dispose M	No	No	6.89	8,972	61.82 k	87,226
17 Dec 24	Alexandra Balcom	Stock Option Class A Common Stock	Option exercise	Dispose M	No	No	1.08	4,728	5.11 k	196,156
16 Dec 24	James Richard Porter	Class A Common Stock	Sell	Dispose S	No	Yes	86.96	8,031	698.38 k	188,113
16 Dec 24	James Richard Porter	Class A Common Stock	Sell	Dispose S	No	Yes	86.46	18,969	1.64 mm	196,144
16 Dec 24	James Richard Porter	Class A Common Stock	Option exercise	Acquire M	No	Yes	27.85	27,000	751.95 k	215,113
16 Dec 24	James Richard Porter	Stock Option Class A Common Stock	Option exercise	Dispose M	No	Yes	27.85	27,000	751.95 k	339,780

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

BMO Capital Maintains Outperform on Nuvalent, Raises Price Target to $134

BMO Capital analyst Etzer Darout maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $132 to $134.

Nuvalent Q3 2024 GAAP EPS $(1.28) Misses $(0.93) Estimate

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.93) by 37.63 percent.

UBS Initiates Coverage On Nuvalent with Neutral Rating, Announces Price Target of $100

UBS analyst David Dai initiates coverage on Nuvalent (NASDAQ:NUVL) with a Neutral rating and announces Price Target of $100.

JP Morgan Maintains Overweight on Nuvalent, Raises Price Target to $125

Press releases

From Benzinga Pro

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,

Nuvalent Appoints Grant Bogle to Board of Directors

CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass, Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.